The stock of Veracyte Inc (VCYT) has seen a -7.38% decrease in the past week, with a -11.40% drop in the past month, and a -24.85% decrease in the past quarter. The volatility ratio for the week is 3.70%, and the volatility levels for the past 30 days are at 3.75% for VCYT. The simple moving average for the last 20 days is -7.32% for VCYT’s stock, with a simple moving average of -21.52% for the last 200 days.
Is It Worth Investing in Veracyte Inc (NASDAQ: VCYT) Right Now?
Company’s 36-month beta value is 1.66.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VCYT is 73.81M, and currently, short sellers hold a 4.93% ratio of that floaft. The average trading volume of VCYT on April 19, 2024 was 636.30K shares.
VCYT) stock’s latest price update
Veracyte Inc (NASDAQ: VCYT)’s stock price has gone rise by 1.80 in comparison to its previous close of 18.86, however, the company has experienced a -7.38% decrease in its stock price over the last five trading days. InvestorPlace reported 2024-02-26 that While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Analysts’ Opinion of VCYT
Many brokerage firms have already submitted their reports for VCYT stocks, with Needham repeating the rating for VCYT by listing it as a “Buy.” The predicted price for VCYT in the upcoming period, according to Needham is $33 based on the research report published on February 23, 2024 of the current year 2024.
Scotiabank gave a rating of “Sector Outperform” to VCYT, setting the target price at $33 in the report published on January 05th of the previous year.
VCYT Trading at -14.47% from the 50-Day Moving Average
After a stumble in the market that brought VCYT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.09% of loss for the given period.
Volatility was left at 3.75%, however, over the last 30 days, the volatility rate increased by 3.70%, as shares sank -11.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.56% lower at present.
During the last 5 trading sessions, VCYT fell by -7.38%, which changed the moving average for the period of 200-days by -22.95% in comparison to the 20-day moving average, which settled at $20.60. In addition, Veracyte Inc saw -30.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VCYT starting from EASTHAM KARIN, who sale 10,000 shares at the price of $21.65 back on Apr 01 ’24. After this action, EASTHAM KARIN now owns 33,125 shares of Veracyte Inc, valued at $216,528 using the latest closing price.
JONES EVAN/ FA, the Director of Veracyte Inc, sale 10,000 shares at $24.36 during a trade that took place back on Mar 01 ’24, which means that JONES EVAN/ FA is holding 37,601 shares at $243,599 based on the most recent closing price.
Stock Fundamentals for VCYT
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.67 for the gross margin
The net margin for Veracyte Inc stands at -0.2. The total capital return value is set at -0.05. Equity return is now at value -7.02, with -6.40 for asset returns.
Based on Veracyte Inc (VCYT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 3.5. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -3693.71.
Currently, EBITDA for the company is 15.12 million with net debt to EBITDA at -4.5. When we switch over and look at the enterprise to sales, we see a ratio of 3.43. The receivables turnover for the company is 8.01for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.66.
Conclusion
In a nutshell, Veracyte Inc (VCYT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
